Rogaine Sales Climb 30% as GLP-1 Use Grows
Personal-care sellers should watch how Kimberly-Clark's $36 billion Kenvue deal reshapes competition in hair-loss products.
Updated on Nov. 5, 2026 in Consumer Goods

Live Poll
Have you or someone you know changed hair-care habits while taking weight loss drugs?
Kimberly-Clark reported third-quarter net sales of $4.1 billion, down 0.4% from a year earlier, while Rogaine sales rose 30% year-to-date after the company completed its roughly $36 billion Kenvue acquisition earlier this week. Operators in consumer health and personal care should note the deal brought Rogaine and several other mass-market brands into Kimberly-Clark's portfolio.
Why it matters
The Rogaine growth is being tied by management to rising use of GLP-1 weight loss drugs, some of which cause hair loss, pointing to a demand category that may be shifting with drug adoption. Kimberly-Clark needed substantial outside financing for the Kenvue takeover, which makes its growth in this category a near-term priority.
Kimberly-Clark reported third-quarter net sales of $4.1 billion, down 0.4% from a year earlier, while Rogaine sales rose 30% year-to-date. The Kenvue deal is valued at roughly $36 billion, including $6.7 billion in cash, with JPMorgan Chase supplying $7.7 billion in bridge financing.
The players
Kimberly-Clark
A large consumer products manufacturer whose portfolio spans household and personal care brands, now expanded through its acquisition of Kenvue.
Kenvue
A consumer health company whose brands include Tylenol, Band-Aid, Benadryl, Listerine and Neutrogena, acquired by Kimberly-Clark in a deal valued at roughly $36 billion.
JPMorgan Chase
A major U.S. bank that supplied $7.7 billion of bridge financing for the Kenvue transaction.
The details
Rogaine reached Kimberly-Clark through its purchase of Kenvue, which also makes Tylenol, Band-Aid, Benadryl, Listerine and Neutrogena lotion. Kimberly-Clark weighed a bond offering in October to help finance the takeover, and the deal closed earlier in the week of November 5. CEO Mike Hsu said the Rogaine sales increase may be driven by adoption of GLP-1 weight loss drugs, as some people taking these medications lose hair.
Timeline
October 2026: Kimberly-Clark weighed a bond offering to finance the Kenvue takeover.
Earlier the week of November 5, 2026: Kimberly-Clark completed the Kenvue acquisition.
Thursday, November 5, 2026: Kimberly-Clark earnings call where Rogaine sales were discussed.
Market Landscape
Kimberly-Clark's acquisition of Kenvue brings Rogaine into a consumer-goods portfolio that competes in mass-market personal care, and Procter & Gamble has responded with a hair-loss-oriented version of its Pantene brand. The deal's scale, roughly $36 billion, puts Kimberly-Clark's consolidation of consumer health brands in direct view of other large household-products companies.
Operators in personal care and consumer health should watch how Kimberly-Clark prices and markets Rogaine as the Kenvue brands are integrated. Businesses that sell GLP-1-adjacent or hair-care products may see shifting demand patterns, and firms should review supplier and distribution terms as larger consolidated competitors take shape.
The takeaway
The Kimberly-Clark and Kenvue combination shows how large consumer-goods companies are using acquisitions to build out health and personal-care portfolios. Operators should track next-quarter Rogaine sales against GLP-1 adoption trends, and consider how a consolidated competitor's pricing might affect their own shelf position.
Further reading
For more on how brand consolidation is reshaping the category, see our Consumer Goods coverage.
Source note: This article includes information reported by Quartz.
Live Poll
Have you or someone you know changed hair-care habits while taking weight loss drugs?




